Changing pattern of end-stage renal disease in central and eastern Europe

Boleslaw Rutkowski, on behalf of the Central Eastern European (CEE) Advisory Board in Chronic Renal Failure (CRF)1, Scientific Advisory Board of the ERA–EDTA Registry Department of Nephrology, Medical University of Gdansk, Poland,2

1 CEE Advisory Board in CRF: Vladimir Teplan (Prague, Czech Republic), Zvonimir Puretic (Zagreb, Croatia), Valery Pilotovich (Minsk, Byelorussia), Natalia Tomilina and Irina Tareyeva (Moscow, Russia), Istvan Kiss (Budapest, Hungary), Alexandrou Ciocalteu (Bucarest, Romania), Ljubica Djukanovic (Belgrade, Yugoslavia), Miroslav Mydlik (Kosice, Slovakia), Stefan Krivoshiev (Sofia, Bulgaria), Rado Kveder (Ljubliana, Slovenija), Momir Polenakovic (Skopje, Macedonia), Merike Luman (Talinn, Estonia), Rafail Rozental (Riga, Latvija), Maria Stanaityte (Vilnius, Lithuania) 2 Scientific Advisory Board of the ERA–EDTA Registry: J. Douglas Briggs, Dimitri Tsakiris, Benedicte Stengel, Izhar Khan, Elizabeth H. Jones, Otto Mehls, Joao Pinto dos Santos

Correspondence and offprint requests to: Prof. Boleslaw Rutkowski, Department of Nephrology, Medical University, Debinki 7, 80-211 Gdansk, Poland.

Abstract

Background. The epidemiology of end-stage renal disease (ESRD) is changing all over the world. Particularly dramatic changes of the epidemiology of ESRD have occurred in central and eastern Europe (CEE). The aim of the present study was (i) to document the further expansion of renal replacement therapy (RRT) noted in recent years in CEE and (ii) to analyse in some detail treatment modalities and underlying renal conditions.

Methods. Three independent surveys were performed in 1995, 1997 and 1998. Fifteen CEE countries participated. The data were mainly obtained from national registries which are based on centre and patient questionnaires.

Results. The data collected from 15 CEE countries document further expansion of RRT in this region. The report includes data on the availability of RRT in Byelorussia, Estonia, and Russia which have become available for the first time. The epidemiology of dialysed patients has changed remarkably. In the majority of countries the number of diabetic patients has increased, most dramatically so in the Czech Republic (31% of all dialysed patients), in the majority of the other countries 10–14%. The number of ESRD patients with the diagnosis of hypertensive nephropathy has also increased and this was accompanied by an increase in proportion of elderly (>65 years) patients, i.e. 46% in the Czech Republic and 12–25% in most other countries.

Conclusion. Dramatic changes of the availability of RRT treatment have occurred in central and eastern Europe. The proportion of diabetic nephropathy and elderly patients has risen. Large differences in RRT exist between individual CEE countries and this appears mainly dependent on the level of economic development.

Keywords: ESRD epidemiology; diabetic nephropathy; central and eastern Europe; renal replacement therapy

Introduction

Three years ago [1] we reported on the epidemiology of end-stage renal disease (ESRD) and renal replacement therapy (RRT) in countries of central and eastern Europe (CEE). The evolution of RRT has recently gained momentum and notable changes in the composition of the patient population and in the use of different treatment modalities have occurred.

In the past reports have been incomplete to the extent that reliable data from Russia had not been available.

The present report gives an update on the epidemiology of RRT in the CEE countries, gives for the first time data concerning Russia, and details the epidemiology of some underlying renal diseases.

Subject and methods

The data are based on three independent surveys performed in 1995, 1997 and 1998 by the CEE Advisory Board on chronic renal failure. Special questionnaires were filled in by the members of the board using data from the national registries or collection of information from local renal units. National reports based on annual centre, or centre and patient, questionnaires were used for verification [25] and, in addition, national registries or their board members were contacted. Data concerning the period 1990–1992 were verified using ERA–EDTA Registry reports [6,7]. The data were also analysed by the Scientific Advisory Board (SAB) of the ERA–EDTA Registry. The data concerned 14 countries, i.e. Bulgaria, Byelorussia, Croatia, Czech Republic, Estonia, Hungary, Latvija, Lithuania, Macedonia, Poland, Romania, Slovakia, Slovenia, Yugoslavia subject to detailed analysis. In addition, the first comprehensive data from Russia were included which were collected by a special team of the Russian Society of Nephrology and concerned the year 1998.

Results

The current state of renal replacement therapy in the CEE countries is given in Table 1.Go


View this table:
[in this window]
[in a new window]
 
Table 1. Renal replacement therapy in central and eastern Europe–1998
 
In the 14 countries (excluding Russia) 38860 patients were on RRT at the end of 1998, i.e. 293 pmp. Of these 78% were treated with different modalities of dialysis and 22% lived with a functioning graft. If Russia was included, the respective figures would be 46759 patients and 166 pmp respectively.

The proportion of transplanted patients differs between countries. The percentage is lowest in Slovakia, Bulgaria and Yugoslavia, intermediate in Russia, Croatia, Byelorussia or Macedonia, good in the Czech Republic, Hungary and Poland and best in the Baltic countries (Estonia, Latvija, Lithuania).

In the CEE countries the average incidence of patients admitted for RRT was 77 pmp, but in nearly half the countries it exceeded 100 pmp. Although progress has been achieved in the past few years in many countries, a very low incidence, i.e. number of patients admitted, is still seen in Byelorussia, Romania and Russia. More than 10% of the dialysed patients were treated using peritoneal dialysis, but striking differences between countries were seen, the proportions ranging from 1% in Macedonia to 49% in Estonia.

Nearly half of the dialysed patients were treated with erythropoetin, but large differences between countries were observed, e.g. 15–20% in Yugoslavia and Russia, 30–49% in Romania, Estonia, Croatia, 60–70% in the Czech Republic, Latvija and Poland, 70–90% in Hungary and Lithuania. The proportions of patients receiving EPO showed some correlation to the Gross National Product per capita.

During the last 8 years an increasing number of diabetic patients admitted for RRT was noted in three of the four countries which were analysed in this respect, i.e. Byelorussia, the Czech Republic and Poland, but not in Croatia where the proportion of diabetic patients was stable at 10–12%, although this country has very good dialysis facilities (Figure 1aGo).



View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1. Changes in the percentage of patients with diabetic (a) and hypertensive nephropathy (b) among dialysed in four countries representing central and eastern Europe. (Countries shown above were selected as an example using four level of dialysis availability: poor, Byelorussia; moderate, Poland; good, Czech Republic; very good, Croatia.).

 
An increasing number of patients diagnosed as having hypertensive nephropathy was noted in Byelorussia and Poland. In contrast, in the Czech Republic the number of patients with this diagnosis decreased and it was stable in Croatia (Figure 1bGo).

There was a remarkable change in the average age of dialysed patients. The number of patients who were more than 65 years of age increased in all of the four countries analysed in this respect despite the different levels of development of dialysis facilities (Table 2Go). This was most pronounced in the Czech Republic and in Croatia where nearly half and a quarter of dialysed patients, respectively, were in this age bracket.


View this table:
[in this window]
[in a new window]
 
Table 2. Changes in the age distribution of patients on dialysis in four selected countries of central and eastern Europe.
 
Discussion

The above data confirm the dramatic development of RRT in CEE. In comparison to our previous report [1] we now include data from Russia and the former satellites of the Soviet Union, i.e. Byelorussia and Estonia, which have become available for the first time. In these countries, renal care for ESRD patients is still problematic, although it is of note that within Russia the availability of RRT is not uniform. In the regions of Moscow and St. Petersburg, respectively, the availability of dialysis and renal transplantation is satisfactory, but in rural areas the chances of a patient with ESRD to obtain access to any type of RRT are poor. On the other hand, substantial progress has been achieved within the space of a few years in the Baltic countries, i.e. Estonia, Latvija and Lithuania as well as in Romania and Poland [8,9].

It is striking that in many countries, e.g. Slovakia, Bulgaria, Romania, Yugoslavia, Slovenia or Macedonia, renal transplantation is still neglected, although in the long run this treatment modality is much cheaper than any form of dialysis — a point of note in this economically underdeveloped part of the world.

This is the first report giving information on the incidence, i.e. patients admitted with end-stage renal failure, in the CEE region. The average incidence (72 pmp) is far lower than figures reported from Japan [10], the United States [11] or Germany [12], but it is close to the figures reported from Australia and New Zealand [13] or Great Britain [14]. In six countries of the CEE region, the incidence was above 100 pmp and in a further six countries it was above 50 pmp.

In the majority of the countries peritoneal dialysis as a treatment modality has become available only during the last few years. For example, in Macedonia the first CAPD treatment of young children was performed in 1997. Actually, in the region no less than 10% of ESRD patients are treated using this modality. The development of CAPD was particularly dramatic in the Baltic countries, and in Romania and Poland [15]. On the other hand, the use of this method decreased during the last 3 years in Hungary and in Slovakia, possibly reflecting a negative impact of privatization in the dialysis sector in these countries.

Erythropoetin is important for the outcome and quality of life in dialysed patients. This medication is available for nearly half of the ESRD patients in the CEE region [16], the availability of erythropoetin is less in CEE countries with less developed economies.

A burning issue is how countries of the CEE region which have RRT programmes in the stage of development will be able to cope with the rising number of patients with diabetes and hypertensive nephropathy [1721]. As illustrated in Figure 1Go, despite differing levels of RRT availability, the number of patients with ESRD and diabetes as a co-morbid condition is still increasing in the majority of CEE countries. Such increase was most dramatic in the Czech Republic where diabetic patients currently account for 31% of patients on dialysis. The majority of these patients suffer from type II diabetes and 58% of them are older than 50 years [4].

In Poland the absolute number of diabetic patients on dialysis increased by a factor of 4 during the past 6 years [22]. Currently close to 12% of all patients on maintenance haemodialysis have diabetes and diabetic patients account for 17% of newly accepted patients [5]. The ratio of type 1 and type 2 diabetes is 1:1. Even in countries with lower rates of acceptance, e.g. Byelorussia or Romania, a sharp increase has been noted. It remains to be examined why in some countries with well-developed RRT systems, e.g. Croatia, Yugoslavia, Slovenia, Macedonia, Slovakia and Hungary, the proportion of diabetic patients amongst the dialysed patients has remained relatively stable in the past few years. This is particularly remarkable, since the number of diabetic patients in these regions is increasing [19]. The number of patients admitted with the diagnosis of hypertensive nephropathy is also increasing in some but not all countries in the CEE region. We are aware of the potential pitfalls of this diagnosis. It is remarkable that in countries with well-developed renal services, e.g. the Czech Republic or Croatia, only 3–4% of the dialysed patients were diagnosed as having hypertensive nephropathy. In the majority of Western European countries approximately 27–28% of dialysed patients are diagnosed as having hypertensive nephropathy.

In parallel with observations in Western Europe [23] and the USA [24] a dramatic increase of elderly patients has been observed in the CEE region and this is most pronounced in the Czech Republic where no less than approximately 50% of patients are above age 65 years and nearly 60% above 60 years [4]. The figures may be artifactually high, however, because of the high transplantation activity in the Czech Republic, since young patients are transplanted preferentially. To a lesser extent, however, an increase of elderly patients is seen throughout the CEE region.

The above results document that the dramatic development in the somewhat heterogeneous CEE countries replicates to differing degrees the epidemiological development which has been noted in Western Europe and in the USA.

Acknowledgments

The authors thank the numerous colleagues in the different countries of central and eastern Europe who participated in the collection of data. We appreciate the encouragement and help provided by Prof. E. Ritz in preparing this communication.

References

  1. Rutkowski B, Ciocalteu A, Djukanovic L et al. Evolution of renal replacement therapy in central and eastern Europe 7 years after political and economical liberation. Nephrol Dial Transplant 1997; 13: 860–864[Abstract]
  2. Dialysis activity in Slovak Republic, Uzis, Bratislava, 1996
  3. Die Tatigkeit und Ergebnisse des Euro Care nephrologischen Netzwerkes im Jahre 1977, Budapest Euro Care Hungary, 1998
  4. Annual report on dialysis treatment in Czech Republic— 1998, Janssen Cilag CR, Prague, 1999
  5. Puka J, Rutkowski B, Liberek T, Bautembach S, Lao M, Rowinski W. Report on renal replacement therapy in Poland 1998. AMG, Gdansk, 1999
  6. Geerlings W, Tufveson G, Brunner FP et al. Combined report on regular dialysis and transplantation in Europe, XXI, 1990. Nephrol Dial Transplant 1991; 6: [Suppl 4]: 5–29[Abstract]
  7. Raine AEG, Margreiter R, Brunner FP, et al. Report on management of renal failure in Europe XXII, 1991. Nephrol Dial Transplant 1992; 7 [Suppl 2]: 7–35[ISI][Medline]
  8. Rutkowski B, Puka J, Lao M, et al. Renal replacement therapy in an era of socioeconomic changes — report from the Polish Registry. Nephrol Dial Transplant 1997; 12: 1105–1108[Abstract]
  9. Petersons A, Ritz E. Nephrology in the Baltic countries. Nephrol Dial Transplant 1998; 13: 2779–2780[Free Full Text]
  10. Shinzato T, Nakai S, Akiba T et al. Current status of renal replacement therapy in Japan: results of the annual survey of the Japanese Society for Dialysis Therapy. Nephrol Dial Transplant 1997; 12: 889–898[Abstract]
  11. US Renal Data system, USRDS 1998 Annual Data report National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, 1998
  12. Frei U, Schober-Halstenberg H-J and the QuaSi-Niere Task Group for Quality Assurance in Renal Replacement Therapy. Annual Report of the German Renal Register 1998. Nephrol Dial Transplant 1999; 14: 1085–1090[Abstract]
  13. Disney APS. Some trends in renal replacement therapy in Australia and New Zealand, 1997. Nephrol Dial Transplant 1998; 13: 854–869[Abstract]
  14. Mallick NP. The costs of renal services in Britain. Nephrol Dial Transplant 1997; 12 [Suppl 1]: 25–28[Abstract]
  15. Rutkowski B on behalf of the CEE Advisory Board in CRF. Progress in peritoneal dialysis in Central and Eastern Europe. Int J Artif Organs 1998; 21: 597 (abstract)
  16. Rutkowski B with Central and Eastern European Advisory Board in Chronic Renal Failure. Erythropoetin treatment in Central and Eastern Europe. Przegl Lek 1998; 55 [Suppl 1]: 147–154
  17. Raine AEG. The rising tide of diabetic nephropathy—the warning before the flood? Nephrol Dial Transplant 1995; 11 [Suppl 8]: 59–64
  18. McCarty D, Zimmet P. Diabetes 1994 to 2010: Global estimates and projections. Melbourne, Australia International Diabetes Institute, 1994
  19. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025. Prevalence, numerical estimates and projections. Diabetes Care 1998; 21: 1414–1431[Abstract]
  20. Valderrabano F, Gomez-Campdera F, Jones EMP. Hypertension as cause of end-stage renal disease: Lessons from international registries. Kidney Int 1998; 54 [Suppl 68]: 560–566
  21. Rutkowski B, Tylicki L, Manitius J, Szydlowska-Lysiak W. Hypertensive nephropathy — an increasing clinical problem. Miner Electrolyte Metab 1999; 25: 65–68[ISI][Medline]
  22. Rutkowski B, Lizakowski S, Rutkowski P, Zdrojewski Z, Puka J. Renal replacement therapy in patients with diabetic nephropathy in Poland. Diabetologia Polska 1997; 4: 227–234
  23. Mignon F, Michel C, Mentre F, Viron B. Worldwide demographies and future trends of the management of renal failure in the elderly. Kidney Int 1993; 43 [Suppl. 41]: 518–526
  24. Ismail N. Renal replacement therapy in the elderly: an old problem with young solutions. Nephrol Dial Transplant 1997; 12: 873–876[Free Full Text]
  25. The World Almanac and Book of Facts 1999. A Primedia Company, New Jersey 1999; 767–861